Normalization of elevated liver enzymes due to V-1 Immunitor therapy
Full Text
Reprint PDF

Keywords

AIDS
hepatitis
oral
therapeutic
transaminase
vaccine

How to Cite

1.
Jirathitikal V, Metadilogkul O, Bourinbaiar AS. Normalization of elevated liver enzymes due to V-1 Immunitor therapy. Electron. J. Biotechnol. [Internet]. 2003 Apr. 15 [cited 2024 Dec. 4];6(1):0-. Available from: https://www.ejbiotechnology.info/index.php/ejbiotechnology/article/view/v6n1-3

Abstract

V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1's effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.

Full Text
Reprint PDF

Upon acceptance of an article by the journal, authors will be asked to transfer the copyright to Electronic Journal of Biotechnology, which is committed to maintain the electronic access to the journal and to administer a policy of fair control and ensure the widest possible dissemination of the information. The author can use the article for academic purposes, stating clearly the following: "Published in Electronic Journal of Biotechnology at DOI:10.2225/volXX-issueX-fulltext-XX".

The Copyright Transfer Agreement must be submitted as a signed scanned copy to biotec@ucv.cl. All authors must send a copy of this document.